Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 28;15(3):813.
doi: 10.3390/cancers15030813.

CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

Hsuan-Jen Lin  1   2 , Rouh-Mei Hu  2 , Hung-Chih Chen  1 , Chung-Chih Lin  1 , Chi-Yu Lee  1 , Che-Yi Chou  1   3   4   5
Affiliations
Review

CA125 for the Diagnosis of Advanced Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

Hsuan-Jen Lin et al. Cancers (Basel). .

Abstract

Background: Urothelial carcinoma of the bladder (UCB) is the second most common genitourinary cancer. This study aims to assess the diagnostic accuracy of CA125 in advanced UCB.

Methods: We searched prevalent studies in PubMed, the Cochrane Library, Scopus, Embase, the Web of Science China National Knowledge Infrastructure database, and Wanfang data before October 2022. Pooled sensitivity, specificity, and summary receiver operating characteristics were used to assess the diagnostic value of CA125.

Results: One thousand six hundred forty-one patients from 14 studies were analyzed. UCB stage T3-4N1 was defined as advanced UCB in ten studies; T2-4 was used in three studies; and N1M1 in one study. Patients' age was between 21 to 92, and 21% to 48.6% of patients were female. The pooled sensitivity was 0.695 (95% confidence interval (CI): 0.426-0.875). The pooled specificity was 0.846 (95% CI: 0.713-0.924). The diagnostic odds ratio was 8.138 (95% CI: 4.559-14.526). The AUC was 0.797.

Conclusion: CA125 may provide significant diagnostic accuracy in identifying muscle-invasive, lymph node-involved, and distant metastatic tumors in patients with urothelial carcinoma of the bladder. Limited studies have been conducted on the prognostic role of CA125. More studies are needed for a meta-analysis on the prognostic role of CA125 in UCB.

Keywords: CA125; bladder cancer; diagnosis; meta-analysis; urothelial cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram for systematic review. WOS: web of science; CNKI: China National Knowledge Infrastructure.
Figure 2
Figure 2
Forest plots of the pooled sensitivity and specificity of CA125 for advanced urothelial carcinoma of the bladder [14,18,19,20,21,22,23,24,25,26,27,28,29,30].
Figure 3
Figure 3
Forest plots of the diagnostic odds ratio of CA125 in the diagnosis of advanced urothelial carcinoma of the bladder [14,18,19,20,21,22,23,24,25,26,27,28,29,30].
Figure 4
Figure 4
The summary receiver operating characteristic (SROC) curve of CA125 in the diagnosis of advanced urothelial carcinoma of the bladder.
Figure 5
Figure 5
Summary of methodological quality of all studies using the QUADAS-2 [14,18,19,20,21,22,23,24,25,26,27,28,29,30].
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Lenis A.T., Lec P.M., Chamie K., Mshs M.D. Bladder Cancer: A Review. JAMA. 2020;324:1980–1991. doi: 10.1001/jama.2020.17598. - DOI - PubMed
    1. Antoni S., Ferlay J., Soerjomataram I., Znaor A., Jemal A., Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur. Urol. 2017;71:96–108. doi: 10.1016/j.eururo.2016.06.010. - DOI - PubMed
    1. Babjuk M., Böhle A., Burger M., Capoun O., Cohen D., Compérat E.M., Hernández V., Kaasinen E., Palou J., Rouprêt M., et al. EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur. Urol. 2016;71:447–461. doi: 10.1016/j.eururo.2016.05.041. - DOI - PubMed
    1. Islami F., Goding Sauer A., Miller K.D., Siegel R.L., Fedewa S.A., Jacobs E.J., McCullough M.L., Patel A.V., Ma J., Soerjomataram I., et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA A Cancer J. Clin. 2017;68:31–54. doi: 10.3322/caac.21440. - DOI - PubMed